Every breath we take can be a doorway for disease. Viruses like COVID-19, influenza, and RSV often enter through the nose, which then becomes the body’s first line of defense. Yet, despite this clear path of infection, most vaccines are still given by injection far from this site, leaving mucosal surfaces under-protected and allowing viruses to enter and replicate before the immune system can respond. For years, this problem has persisted due to the complexity of delivering large molecules through the nasal cavity. Sinedore developed NasoPass™ to resolve this problem and to initiate immunity at the point of viral entry.
Breaking Through Nasal Barriers
Delivering vaccines through the nose is not as simple as spraying liquid into the airway. The nasal cavity is designed to trap and clear foreign substances, with a thick mucus layer and immune defenses that block most formulations. Many existing intranasal vaccines fail to reach their target: antigen-presenting cells beneath the mucosal surface. NasoPass™ overcomes these physical and immunological barriers through optimized formulation and retention. The platform enhances penetration across the mucosal layer and extends the time vaccines remain in the nasal cavity, allowing for deeper immune engagement and better antigen uptake.
Restoring Local and Systemic Immunity
Conventional injections focus on generating systemic IgG antibodies but miss the mucosal IgA response critical to stopping respiratory viruses early. NasoPass™ activates both layers of immunity: mucosal IgA at the entry point and systemic IgG throughout the body. This dual effect not only boosts overall protection but also supports stronger immune memory, reducing the chance of reinfection. By enabling this comprehensive response, NasoPass™ addresses the limitations of both injected and standard nasal vaccines and offers a more complete defense against respiratory disease.
Evidence of Enhanced Protection
Preclinical studies of NasoPass™ show an 99% increase in nasal IgA and a 239% increase in serum IgG, demonstrating robust activation of both local and systemic immunity. Importantly, these responses extended beyond the nasal cavity to immune organs like the spleen, confirming that NasoPass™ engages the full immune network. These results indicate more than efficient delivery—they reflect the potential of a platform that may help redefine vaccine performance.
Beyond Vaccines
While vaccines are the immediate focus, NasoPass™ is designed for other uses as well. The platform delivers large molecules like peptides, proteins, and hormones via the nasal route, offering a needle-free alternative to injectables for respiratory and endocrine conditions. The potential for self-administration improves access and convenience, especially in long-term care. By removing the pain and complexity of injections, NasoPass™ enables more sustainable treatment strategies.
NasoPass™ isn’t just a new tool. It’s a new approach. By solving the core problem of poor mucosal immunity and nasal delivery inefficiency, the platform redefines how we prepare for respiratory threats. As global health systems face continued pressure from airborne infections, innovations like NasoPass™ make vaccination more effective, more accessible, and more aligned with how diseases actually spread. For Sinedore, the future of prevention begins at the source—with every breath.
